Antipathy from figures close to Trump toward mRNA technology, which underlies Moderna’s products and pipeline, has weighed on ...

Moderna’s second quarter results were met with a negative market reaction, as investors focused on both a sharp decline in ...

Moderna may offer substantial upside, but it's essential to consider the associated risks. Since hitting their peak in late ...

Moderna (MRNA) skyrocketed to fame during the pandemic, delivering one of the first mRNA-based Covid-19 vaccines and quickly ...

Moderna said today it would trim roughly 10% of its global workforce and have fewer than 5,000 employees by the end of the year as the biotech accelerates its cost-cutting efforts amid declining sales ...

Moderna trimmed its 2025 revenue forecast on Friday after UK deliveries of some COVID vaccines were deferred to next year, ...

What Happened? A number of stocks jumped in the morning session after positive inflation data fueled hopes for an interest rate cut by the Federal Reserve. The latest Consumer Price Index (CPI) report ...

It’s not often that a CEO outright dismisses M&A prospects, but Moderna CEO Stéphane Bancel says the mRNA biotech has enough ...

In a memo to employees, Moderna CEO Stephane Bancel said the company expects to have fewer than 5,000 workers by the end of ...

The layoffs are part of an ongoing effort to reduce operating costs amid government and competitive challenges to its vaccine ...

Analysts have given Moderna a total of 6 ratings, with the consensus rating being Neutral. The average one-year price target ...

Moderna on Thursday said its 2023 sales would only hit the low end of its $6 billion to $8 billion forecast, reflecting weaker demand for COVID-19 vaccines, and its shares slumped 8%.